Accessibility StatementSkip Navigation CHICAGO, Sept. 10, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, revealed today that U.S. employer health care costs are projected to rise 9.5 percent* in 2026, exceeding $17,000 per employee. This marks the third consecutive year of elevated health care cost trends near double digits. The continued rise in chronic conditions, such as musculoskeletal and cardiovascular disease, alongside an increase in high-cost conditions like ...

Headwinds such as extreme weather, inflation and line-specific pressures continue to challenge long-term underwriting profitabilityJERSEY CITY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, and The American Property Casualty Insurance Association (APCIA), the primary national trade association for home, auto and business insurers, today reported half-year underwriting gains for the insurance industr ...

Core Viewpoint - Tevogen Bio Holdings Inc. is expanding its AI-driven platform, Tevogen.AI, to enhance patient data integration for clinical trial participant identification, aiming to accelerate the development of personalized T cell therapies [1][2][3] Group 1: Tevogen.AI and PredicTcell™ - Tevogen.AI, supported by Microsoft and Databricks, will analyze electronic health records and real-world patient data to identify potential clinical trial participants [2] - The integration of patient data with the PredicTcell™ model is expected to enhance the ExacTcell™ pipeline development [2][3] Group 2: Clinical Trial Efficiency - Tevogen.AI aims to improve clinical trial efficiency, scalability, and inclusivity by rapidly identifying and enrolling suitable patients [3] - The initiative is designed to address critical bottlenecks in clinical development, potentially accelerating time-to-market for new therapeutic interventions [3][6] Group 3: Strategic Goals - The company’s mission focuses on achieving commercially attractive, economically viable, and cost-effective personalized T cell therapies [3] - By enhancing patient outcomes and expediting therapeutic approvals, Tevogen.AI seeks to provide a foundation for commercial success and investment growth [3]